Escitalopram

Generic Name: Escitalopram

Brand Names: Cipralex, Lexapro

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁FN_₂O

CAS Number: 128196-01-0

Unique Ingredient Identifier: 4O4S742ANY

Background: Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...

Indication: Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...

Associated Conditions: Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)

Associated Therapies: -

Clinical Trials

Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression

Phase 4

Terminated

Conditions: Depression

Interventions: Drug: Escitalopram
Drug: Bupropion

First Posted Date: 2019-06-20

Last Posted Date: 2023-04-18

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 18

Registration Number: NCT03993457

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment

Phase 4

Completed

Conditions: Major Depression

Interventions: Drug: escitalopram
Drug: bupropion

First Posted Date: 2019-04-25

Last Posted Date: 2019-04-25

Lead Sponsor: University of Tartu

Target Recruit Count: 135

Registration Number: NCT03927950

Locations: 🇪🇪
Department of Psychiatry, University of Tartu, Tartu, Estonia

A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder

Phase 4

Completed

Conditions: Anxiety Disorders,Generalized Anxiety Disorder

Interventions: Drug: Escitalopram
Other: Placebo

First Posted Date: 2019-04-23

Last Posted Date: 2022-11-14

Lead Sponsor: AbbVie

Target Recruit Count: 273

Registration Number: NCT03924323

Locations: 🇺🇸
UH Cleveland Medical Center /ID# 233373, Cleveland, Ohio, United States
🇺🇸
Center for Psychiatry and Behavioral Medicine Inc /ID# 233355, Las Vegas, Nevada, United States
🇺🇸
ATP Clinical Research, Inc /ID# 233362, Costa Mesa, California, United States

and more 36 locations

Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo oral capsule
Drug: Escitalopram

First Posted Date: 2019-04-12

Last Posted Date: 2020-12-01

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 27

Registration Number: NCT03912974

Locations: 🇨🇭
University Hospital Basel, Clinical Trial Unit, Basel, BS, Switzerland

Treating Depression With Transcutaneous Electrical Cranial-auricular Acupoint Stimulation (TECAS).

Phase 2

Completed

Conditions: Mild-to-moderate Depression

Interventions: Procedure: TECAS Procedure
Drug: Escitalopram
Drug: Insomnia medication

First Posted Date: 2019-04-09

Last Posted Date: 2024-05-17

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 470

Registration Number: NCT03909217

Locations: 🇨🇳
Department of neurology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China
🇨🇳
Southwest Medical University, Hospital of Traditional Chinese Medicine, Luzhou, Sichuan, China
🇨🇳
Department of Chinese Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China

and more 3 locations

Study on the Effect of PRKCB1 Modulating Inflammatory Factors and the Role for Developing Major Depressive Disorder

Not Applicable

Conditions: Major Depressive Disorder

Interventions: Drug: escitalopram
Dietary Supplement: fish oil capsules

First Posted Date: 2019-04-02

Last Posted Date: 2019-04-02

Lead Sponsor: Shanghai Mental Health Center

Target Recruit Count: 350

Registration Number: NCT03899194

Locations: 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China

Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.

Early Phase 1

Terminated

Conditions: Depressive Disorder, Treatment-Resistant

Interventions: Drug: Placebo
Drug: Ethosuximide
Drug: Escitalopram

First Posted Date: 2019-03-25

Last Posted Date: 2022-05-20

Lead Sponsor: Zhejiang University

Target Recruit Count: 16

Registration Number: NCT03887624

Locations: 🇨🇳
Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

Phase 3

Withdrawn

Conditions: Depressive Disorder, Treatment-Resistant

Interventions: Drug: Esketamine 28 mg
Drug: Placebo
Drug: Esketamine 56 mg
Drug: Esketamine 84 mg
Drug: Escitalopram
Drug: Sertraline
Drug: Duloxetine
Drug: Mirtazapine
Drug: Agomelatine
Drug: Bupropion
Drug: Trazodone Prolonged Release

First Posted Date: 2019-02-25

Last Posted Date: 2019-11-26

Lead Sponsor: Janssen-Cilag International NV

Registration Number: NCT03852160

Contact: Developing New Clinical Management Strategies

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Escitalopram

First Posted Date: 2019-01-23

Last Posted Date: 2022-04-21

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 29

Registration Number: NCT03812588

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Vortioxetine
Drug: Sertraline
Drug: citalopram
Drug: Escitalopram
Drug: Paroxetine
Drug: Fluoxetine
Drug: Fluvoxamine

First Posted Date: 2018-12-19

Last Posted Date: 2023-05-19

Lead Sponsor: Azienda Ospedaliera Universitaria Integrata Verona

Target Recruit Count: 362

Registration Number: NCT03779789

Locations: 🇮🇹
Azienda Ospedaliera Universitaria Mater Domini, Università Magna Grecia, Catanzaro, Italy
🇮🇹
Sapienza Università di Roma, Dipartimento di Neurologia e Psichiatria, Roma, Italy
🇮🇹
Azienda Ospedaliera Universitaria Verona, Verona, Italy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy